Medios AG
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG000BJNVX5
ILM1
Medios AG
GICS: 35102010
·
Sector: Wholesale drugs
·
Sub-Sector: -
NAME
Medios AG
ISIN
DE000A1MMCC8
TICKER
ILM1
MIC
XETR
REUTERS
ILM1k.DE
BLOOMBERG
ILM1 GR
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Tue, 12.11.2024
Press release
Medios AG reports record quarter Q3 2024 with significant increase in earnings and margins
EBITDA pre1 reaches €24.6 million (+42.9%) in the third quarter of 2024, setting a new record
EBITDA pre1 margin of 5.0% in the third quarter of 2024
Patient-Specific Therapies segment grows by more than 10% in EBITDA pre1 compared to the...
Wed, 14.08.2024
Press release
Medios AG: Annual General Meeting resolves to expand the Supervisory Board to five members
Berlin, August 14, 2024 – The shareholders of Medios, a leading provider of Specialty Pharma in Europe, today approved all but two of the resolutions proposed by the Executive Board and Supervisory Board at the Annual General Meeting. A total ...
Tue, 13.08.2024
Press release
Medios AG continues its growth trajectory in the first half of 2024 and records disproportionately high increase in earnings
Revenue increases by 6.3% and EBITDA pre1 by 7.3% in the first half of the year
Cash flow from operating activities increases significantly to €34.0 million
Acquisition of Ceban successfully completed in Jun...
Mon, 05.08.2024
Medios expands „Advanced Therapies“ field and appoints Dr. Andreas Schmiede as Vice President
Berlin, August 5, 2024 – Medios AG (“Medios“), a leading provider of Specialty Pharma in Europe, strengthens its activities in the field of Advanced Therapies and appoints Dr. Andreas Schmiede as Vice President Advanced Therapies. The entry into the Advan...
Mon, 01.07.2024
EQS-Media / 01.07.2024 / 09:32 CET/CEST
Press release“Hauptstadtkongress 2024”: Medios hosts symposium on "Security of supply”
Berlin, July 01, 2024 – Medios AG, a leading provider of Specialty Pharma in Europe, was represented for the first time at the “Hauptstadtkongress” (Capital Congress) in Berlin, which took place from June 26 to June 2...
Thu, 20.06.2024
Press Release
Medios AG: Successful sale of shares from Company founder Manfred Schneider to Luxempart S.A.
Berlin, June 20, 2024 – Medios, a leading provider of Specialty Pharma in Europe, was today informed that Manfred Schneider has reallocated all of his shares in Medios AG. Schneider’s shares, which corresponds to a total of 14.9% of Medios’...
Fri, 07.06.2024
Press Release
Hauck & Aufhäuser starts coverage of Medios AG with buy recommendation and price target of €23.00
Berlin, June 7, 2024 – Hauck & Aufhäuser Investment Banking initiated coverage of Medios AG yesterday and recommended the shares as a “buy”. The price target is €23.00 and thus around 55 percent above the Xetra closing price on ...
Thu, 06.06.2024
Press release
Medios AG successfully completes acquisition of Ceban, significantly expanding its market position in Europe
Berlin, June 06, 2024 – Medios, a leading provider of Specialty Pharma in Europe, has completed the acquisition of Ceban Pharmaceuticals B.V. (“Ceban”), a fast-growing, leading pharmaceutical compounding platform with operati...
Thu, 06.06.2024
Press release
Medios AG successfully completes acquisition of Ceban, significantly expanding its market position in Europe
Berlin, June 06, 2024 – Medios, a leading provider of Specialty Pharma in Europe, has completed the acquisition of Ceban Pharmaceuticals B.V. (“Ceban”), a fast-growing, leading pharmaceutical compounding platform with operati...
Tue, 07.05.2024
Press release
Medios AG records further revenue growth in the first quarter of 2024 and confirms full-year guidance
Revenue increases by 5.8% to €456.2 million in the first quarter
Cash flow from operating activities increases to €43.4 million
Closing of the Ceban acquisition planned for May 2024
Guidance 2024 confirmed: Significant incr...
Information on product placements
